Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by George Bondi on Nov 4th, 2026

Shares of Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $53.00.

KRSA has been the subject of a number of research analyst reports. Zacks Research raised shares of Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday, September 9th. Guggenheim initiated coverage on Cyclerion Therapeutics in a research note on Monday, September 28th. They issued a “buy” rating and a $70.00 target price for the company. UBS Group assumed coverage on shares of Cyclerion Therapeutics in a research note on Friday, September 11th. They set a “buy” rating and a $55.00 price target on the stock. Wall Street Zen upgraded shares of Cyclerion Therapeutics to a “sell” rating in a research note on Saturday, October 3rd. Finally, TD Cowen assumed coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating on the stock.

Check Out Our Latest Report on Cyclerion Therapeutics

Institutional Trading of Cyclerion Therapeutics

Several hedge funds have recently added to or reduced their stakes in KRSA. BlackRock Inc. bought a new stake in shares of Cyclerion Therapeutics in the second quarter worth $57,000. Braidwell LP bought a new position in shares of Cyclerion Therapeutics during the 2nd quarter worth approximately $532,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Cyclerion Therapeutics in the second quarter valued at about $1,013,000. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ KRSA opened at $31.96 on Wednesday. Cyclerion Therapeutics has a one year low of $7.19 and a one year high of $59.36.

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.